A Phase 3 interventional study of Sacituzumab Govitecan-hziy and Paclitaxel in Locally Advanced or Metastatic Unresectable Urothelial Cancer, sponsored by Gilead Sciences. Completed at 234 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to assess overall survival (OS) with sacituzumab govitecan-hziy in comparison with treatment of physician's choice (TPC) in participants with metastatic or locally advanced unresectable urothelial cancer (UC).
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Individuals with documented or locally advanced unresectable UC defined as
Individuals with progression or recurrence following receipt of platinum-containing regimen and anti programmed cell death protein 1/programmed death-ligand 1 (/PD-L1) therapy for metastatic or locally advanced unresectable disease will be enrolled.
Cisplatin ineligible individuals who meet one of the below criteria and who were treated with carboplatin in the metastatic or locally advanced unresectable settings may count that line of therapy towards eligibility. They must then have received anti PD-1/PD-L1 therapy in metastatic or locally advanced unresectable setting to be eligible for the study.
-- Cisplatin ineligibility is defined as meeting one of the following criteria:
Docetaxel will only be option in TPC arm for individuals with a total bilirubin ≤1 x IULN, and an AST and/or ALT ≤1.5x IULN if alkaline phosphatase is also >2.5 x IULN.
Key Exclusion Criteria:
Have active cardiac disease, defined as:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 10 mg/kg of SG intravenously (IV) on Day 1 and Day 8 of each 21-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or another treatment discontinuation criterion is met.
Drug: Sacituzumab Govitecan-hziy
Participants will receive 1 of 3 standard-of-care chemotherapeutic options, as determined by the investigator prior to randomization, and will continue to receive the same treatment for the duration of the study until disease progression, unacceptable toxicity, withdrawal of consent, or another treatment discontinuation criterion is met. Paclitaxel 175 mg/m\^2 IV on Day 1 of every 21-day cycle or Docetaxel 75 mg/m\^2 IV on Day 1 of every 21-day cycle or Vinflunine 320 mg/m\^2 IV on Day 1 of every 21-day cycle (in countries where vinflunine was approved and was commercially available).
Drug: Paclitaxel · Drug: Docetaxel · Drug: Vinflunine
Administered intravenously
Also known as: IMMU-132, Trodelvy™, GS-0132
Administered intravenously
Also known as: Taxol®
Administered intravenously
Also known as: Taxotere®
Administered intravenously
Also known as: Javlor ®
Overall Survival (OS)
OS was defined as time from the date of randomization to the date of death, regardless of cause. Kaplan-Meier (KM) estimates were used for analysis.
Time frame: Up to 42 months
Progression-Free Survival (PFS) by Investigator Assessment
PFS was defined as the time from the date of randomization to the date of the first objectively documented disease progression (PD), per response evaluation criteria in solid tumors (RECIST) v1.1 criteria as determined by investigator assessment, or death regardless of cause, whichever occurs first. PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). KM estimates were used for analysis.
Time frame: Up to 42 months
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR)
PFS is defined as the time from the date of randomization to the date of the first objectively documented disease progression (PD), per RECIST v1.1 criteria as determined by BICR, or death regardless of cause, whichever occurs first. PD was defined in outcome measure (OM) #2. KM estimates were used for analysis.
Time frame: Up to 42 months
Objective Response Rate (ORR) by Investigator Assessment
ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) as best overall response (BOR) as assessed by investigator assessment. CR was defined as disappearance of all target lesions. PR was defined as ≥30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Percentages were rounded off.
Time frame: Up to 42 months
Objective Response Rate (ORR) by BICR
ORR was defined as the percentage of participants who achieved a CR or PR as BOR as assessed by BICR. CR and PR are defined in OM#4. Percentages were rounded off.
Time frame: Up to 42 months
Clinical Benefit Rate (CBR) by Investigator Assessment
CBR was defined as the percentage of participants who achieved a BOR of confirmed CR, PR, or stable disease (SD) for ≥ 6 months, per RECIST v1.1, as assessed by investigator assessment. SD is defined as Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter since the treatment started; PD was defined in OM#2; BOR, CR and PR are defined in OM#4. Percentages were rounded off.
Time frame: Up to 42 months
Clinical Benefit Rate (CBR) by BICR
CBR was defined as the percentage of participants who achieved a BOR of confirmed CR, PR, or SD for ≥ 6 months, per RECIST v1.1, as assessed by BICR. PD was defined in OM#2; BOR, CR and PR are defined in OM#4; SD was defined in OM#6. Percentages were rounded off.
Time frame: Up to 42 months
Duration of Objective Tumor Response (DOR) by Investigator Assessment
DOR was defined as the time from the date when the criteria is first met for a CR or PR to the first date that PD is documented per RECIST 1.1 as determined by investigator assessment, or date of death, whichever occurs first. KM estimates were used in analysis. PD was defined in OM#2, CR and PR are defined in OM#4.
Time frame: Up to 42 months
Duration of Objective Tumor Response (DOR) by BICR
DOR was defined as the time from the date when the criteria is first met for a CR or PR to the first date that PD is documented per RECIST 1.1 as determined by BICR, or date of death, whichever occurs first. KM estimates were used in analysis. PD was defined in OM#2, CR and PR are defined in OM#4.
Time frame: Up to 42 months
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. The SAE was defined as any untoward medical occurrence that at any dose which was fatal (results in death) or life-threatening or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or an important medical event. TEAEs were defined as an AE that onset in the period from the first dose of study treatment to 30 days after the last dose of study treatment. Percentages were rounded off.
Time frame: From first dose up to 33.6 months
Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities
A laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time of postbaseline up to and including the date of last study drug dose plus 30 days. Severity grades were defined by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death. Percentages were rounded off.
Time frame: From first dose up to 33.6 months
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core 30 (EORTC-QLQ-C30) Domain Score
The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer participants, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Domain scores were reported for following scales: Physical Functioning, Global Health Status, Pain, and Fatigue Score. Scoring of the QLQ-C30 was performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the participant). For Symptom scales, a lower score means better quality of life. For Global Health Status and Functional Scales, a higher score signifies better quality of life.
Time frame: Baseline (Day 0)
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core 30 (EORTC-QLQ-C30) Domain Score
The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer participants, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Domain scores were reported for following scales: Physical Functioning, Global Health Status, Pain, and Fatigue Score. Scoring of the QLQ-C30 was performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the participant). For Symptom scales, a lower score means better quality of life. For Global Health Status and Functional Scales, a higher score signifies better quality of life.
Time frame: Cycle 5 Day 1; Cycle length = 21 days
Participants were enrolled at study sites in Asia, Australia, Europe, and North America.
| Milestone | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice |
|---|---|---|
| Started | 355 | 356 |
| Completed | 0 | 0 |
| Not completed | 355 | 356 |
| Withdrew: Death | 293 | 297 |
| Withdrew: Other (not specified) | 37 | 31 |
| Withdrew: Withdrawal of consent | 21 | 27 |
| Withdrew: Lost to follow-up | 4 | 1 |
OS was defined as time from the date of randomization to the date of death, regardless of cause. Kaplan-Meier (KM) estimates were used for analysis.
| months | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice |
|---|---|---|
| Overall Survival (OS) | 10.3 (9.1 to 11.8) | 9.0 (7.5 to 9.7) |
PFS was defined as the time from the date of randomization to the date of the first objectively documented disease progression (PD), per response evaluation criteria in solid tumors (RECIST) v1.1 criteria as determined by investigator assessment, or death regardless of cause, whichever occurs first. PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). KM estimates were used for analysis.
| months | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice |
|---|---|---|
| Progression-Free Survival (PFS) by Investigator Assessment | 4.0 (2.9 to 4.2) | 2.9 (2.8 to 3.5) |
PFS is defined as the time from the date of randomization to the date of the first objectively documented disease progression (PD), per RECIST v1.1 criteria as determined by BICR, or death regardless of cause, whichever occurs first. PD was defined in outcome measure (OM) #2. KM estimates were used for analysis.
| months | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice |
|---|---|---|
| Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) | 4.2 (3.8 to 4.5) | 3.6 (2.9 to 4.2) |
ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) as best overall response (BOR) as assessed by investigator assessment. CR was defined as disappearance of all target lesions. PR was defined as ≥30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Percentages were rounded off.
| percentage of participants | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice |
|---|---|---|
| Objective Response Rate (ORR) by Investigator Assessment | 19.7 (15.7 to 24.2) | 15.7 (12.1 to 19.9) |
ORR was defined as the percentage of participants who achieved a CR or PR as BOR as assessed by BICR. CR and PR are defined in OM#4. Percentages were rounded off.
| percentage of participants | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice |
|---|---|---|
| Objective Response Rate (ORR) by BICR | 22.5 (18.3 to 27.2) | 13.8 (10.4 to 17.8) |
CBR was defined as the percentage of participants who achieved a BOR of confirmed CR, PR, or stable disease (SD) for ≥ 6 months, per RECIST v1.1, as assessed by investigator assessment. SD is defined as Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter since the treatment started; PD was defined in OM#2; BOR, CR and PR are defined in OM#4. Percentages were rounded off.
| percentage of participants | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice |
|---|---|---|
| Clinical Benefit Rate (CBR) by Investigator Assessment | 31.5 (26.7 to 36.7) | 21.9 (17.7 to 26.6) |
CBR was defined as the percentage of participants who achieved a BOR of confirmed CR, PR, or SD for ≥ 6 months, per RECIST v1.1, as assessed by BICR. PD was defined in OM#2; BOR, CR and PR are defined in OM#4; SD was defined in OM#6. Percentages were rounded off.
| percentage of participants | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice |
|---|---|---|
| Clinical Benefit Rate (CBR) by BICR | 29.9 (25.1 to 34.9) | 20.5 (16.4 to 25.1) |
DOR was defined as the time from the date when the criteria is first met for a CR or PR to the first date that PD is documented per RECIST 1.1 as determined by investigator assessment, or date of death, whichever occurs first. KM estimates were used in analysis. PD was defined in OM#2, CR and PR are defined in OM#4.
| months | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice |
|---|---|---|
| Duration of Objective Tumor Response (DOR) by Investigator Assessment | 7.1 (5.8 to 9.0) | 5.8 (3.7 to 7.0) |
DOR was defined as the time from the date when the criteria is first met for a CR or PR to the first date that PD is documented per RECIST 1.1 as determined by BICR, or date of death, whichever occurs first. KM estimates were used in analysis. PD was defined in OM#2, CR and PR are defined in OM#4.
| months | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice |
|---|---|---|
| Duration of Objective Tumor Response (DOR) by BICR | 7.2 (6.3 to 8.4) | 6.5 (5.2 to 8.3) |
An adverse event (AE) was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. The SAE was defined as any untoward medical occurrence that at any dose which was fatal (results in death) or life-threatening or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or an important medical event. TEAEs were defined as an AE that onset in the period from the first dose of study treatment to 30 days after the last dose of study treatment. Percentages were rounded off.
| percentage of participants | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice |
|---|---|---|
| TEAE | 99.4 | 95.0 |
| TESAE | 53.0 | 32.6 |
A laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time of postbaseline up to and including the date of last study drug dose plus 30 days. Severity grades were defined by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death. Percentages were rounded off.
| percentage of participants | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice |
|---|---|---|
| Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities | 68.6 | 36.8 |
The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer participants, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Domain scores were reported for following scales: Physical Functioning, Global Health Status, Pain, and Fatigue Score. Scoring of the QLQ-C30 was performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the participant). For Symptom scales, a lower score means better quality of life. For Global Health Status and Functional Scales, a higher score signifies better quality of life.
| score on scale | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice |
|---|---|---|
| Functional Scales: Physical Functioning: Baseline | 74.6 ± 21.34 | 75.5 ± 21.81 |
| Global Health Status / Quality of life (QoL) : Baseline | 59.6 ± 21.39 | 62.2 ± 21.76 |
| Symptom Scales / Items: Pain : Baseline | 34.3 ± 31.83 | 31.7 ± 28.45 |
| Symptom Scales / Items: Fatigue : Baseline | 35.8 ± 24.34 | 37.4 ± 25.43 |
The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer participants, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Domain scores were reported for following scales: Physical Functioning, Global Health Status, Pain, and Fatigue Score. Scoring of the QLQ-C30 was performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the participant). For Symptom scales, a lower score means better quality of life. For Global Health Status and Functional Scales, a higher score signifies better quality of life.
| score on scale | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice |
|---|---|---|
| Functional Scales: Physical Functioning: Change from Baseline at Cycle 5 Day 1 | -7.3 (-10.1 to -4.5) | -8.4 (-11.4 to -5.4) |
| Global Health Status / QoL : Change from Baseline at Cycle 5 Day 1 | -1.6 (-4.6 to 1.4) | -1.6 (-4.8 to 1.6) |
| Symptom Scales / Items: Pain : Change from Baseline at Cycle 5 Day 1 | -4.2 (-8.2 to -0.3) | -1.5 (-5.7 to 2.7) |
| Symptom Scales / Items: Fatigue : Change from Baseline at Cycle 5 Day 1 | 5.6 (2.0 to 9.1) | 7.6 (3.8 to 11.4) |
Collected over Up to 42 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sacituzumab Govitecan-hziy (SG) | 305/355 (85.9%) | 185/349 (53%) | 341/349 (97.7%) |
| Treatment of Physician's Choice | 310/356 (87.1%) | 110/337 (32.6%) | 303/337 (89.9%) |
| Event | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 37/349 | 15/337 |
| DiarrhoeaGastrointestinal disorders | 30/349 | 6/337 |
| NeutropeniaBlood and lymphatic system disorders | 16/349 | 6/337 |
| Urinary tract infectionInfections and infestations | 16/349 | 11/337 |
| SepsisInfections and infestations | 12/349 | 4/337 |
| PyrexiaGeneral disorders | 11/349 | 7/337 |
| Neutropenic sepsisInfections and infestations | 10/349 | 3/337 |
| Neutrophil count decreasedInvestigations | 10/349 | 4/337 |
| Acute kidney injuryRenal and urinary disorders | 10/349 | 3/337 |
| Septic shockInfections and infestations | 9/349 | 3/337 |
| Event | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 189/349 | 63/337 |
| AnaemiaBlood and lymphatic system disorders | 186/349 | 116/337 |
| NauseaGastrointestinal disorders | 157/349 | 59/337 |
| AlopeciaSkin and subcutaneous tissue disorders | 138/349 | 113/337 |
| FatigueGeneral disorders | 109/349 | 76/337 |
| ConstipationGastrointestinal disorders | 104/349 | 66/337 |
| AstheniaGeneral disorders | 99/349 | 74/337 |
| Decreased appetiteMetabolism and nutrition disorders | 94/349 | 58/337 |
| NeutropeniaBlood and lymphatic system disorders | 92/349 | 23/337 |
| VomitingGastrointestinal disorders | 79/349 | 20/337 |
The Intent-to-treat (ITT) Analysis Set included all participants who have been randomized to the trial.
| Age, Categorical(Participants) | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 133 | 131 | 264 |
| >=65 years | 222 | 225 | 447 |
| Age, Continuous(years) | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice | Total |
|---|---|---|---|
| Mean | 66 ± 9.1 | 67 ± 10.1 | 67 ± 9.6 |
| Sex: Female, Male(Participants) | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice | Total |
|---|---|---|---|
| Female | 71 | 77 | 148 |
| Male | 284 | 279 | 563 |
| Race/Ethnicity, Customized(Participants) | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 1 | 1 |
| Race — Asian | 92 | 82 | 174 |
| Race — Black or African American | 0 | 1 | 1 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Race — White | 194 | 188 | 382 |
| Race — Other or More Than One Race | 1 | 1 | 2 |
| Race — Not Collected | 68 | 83 | 151 |
| Race/Ethnicity, Customized(Participants) | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice | Total |
|---|---|---|---|
| Ethnicity — Not Hispanic or Latino | 279 | 271 | 550 |
| Ethnicity — Hispanic or Latino | 8 | 6 | 14 |
| Ethnicity — Not Collected | 68 | 79 | 147 |
| Region of Enrollment(Participants) | Sacituzumab Govitecan-hziy (SG) | Treatment of Physician's Choice | Total |
|---|---|---|---|
| France | 69 | 81 | 150 |
| Spain | 36 | 52 | 88 |
| China | 42 | 41 | 83 |
| South Korea | 38 | 27 | 65 |
| United Kingdom | 27 | 28 | 55 |
| Italy | 22 | 25 | 47 |
| Belgium | 20 | 22 | 42 |
| Greece | 16 | 14 | 30 |
| Australia | 17 | 11 | 28 |
| Germany | 13 | 13 | 26 |
| Canada | 14 | 5 | 19 |
| Austria | 6 | 5 | 11 |
| Taiwan | 3 | 7 | 10 |
| United States | 6 | 4 | 10 |
| Georgia | 3 | 6 | 9 |
| Israel | 6 | 3 | 9 |
| Portugal | 4 | 3 | 7 |
| Singapore | 4 | 1 | 5 |
| Sweden | 2 | 3 | 5 |
| Ireland | 1 | 2 | 3 |
| Bulgaria | 0 | 2 | 2 |
| Croatia | 1 | 1 | 2 |
| Switzerland | 2 | 0 | 2 |
| Turkey | 2 | 0 | 2 |
| Hong Kong | 1 | 0 | 1 |
Showing the first 100 of 234 sites across 27 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2021 to primary completion in Jul 2025, 53 months.
Results were first posted in Jun 2026, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sacituzumab govitecan